HepaVec AG specializes in the development of novel therapeutic products for malignant and genetic liver diseases. They have created gene transfer systems that efficiently deliver therapeutic genes into human liver cells. Their lead product, which regulates the cell cycle to induce programmed cell death in cancer cells, is set to enter a Phase I/II clinical trial in 2000. HepaVec AG aims to address liver cancer and other liver diseases through their advanced cell engineering techniques.